Studies
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
Request Access
Overview
Selected Publications (5)
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
S. Naggie, D. Boulware, C. Lindsell, et al.. (2022). JAMA. Cited 76 times.
https://doi.org/10.1001/jama.2022.18590
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.
S. Naggie, D. Boulware, C. Lindsell, et al.. (2023). JAMA. Cited 60 times.
https://doi.org/10.1001/jama.2023.1650
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
M. McCarthy, S. Naggie, D. Boulware, et al.. (2023). JAMA. Cited 57 times.
https://doi.org/10.1001/jama.2022.24100
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
Thomas G. Stewart, Pauline Rebolledo, Ahmad Mourad, et al.. (2023). JAMA. Cited 22 times.
https://doi.org/10.1001/jama.2023.23363
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo
Russell L Rothman, Thomas G. Stewart, A. Mourad, et al.. (2024). JAMA Network Open. Cited 4 times.
https://doi.org/10.1001/jamanetworkopen.2024.39332
